[go: up one dir, main page]

HK1253702A1 - 用聚磷酸/聚磷酸酯/聚磷酸鹽或雙膦酸/雙膦酸酯/雙膦酸鹽穩定的無定形碳酸鈣 - Google Patents

用聚磷酸/聚磷酸酯/聚磷酸鹽或雙膦酸/雙膦酸酯/雙膦酸鹽穩定的無定形碳酸鈣

Info

Publication number
HK1253702A1
HK1253702A1 HK18112849.8A HK18112849A HK1253702A1 HK 1253702 A1 HK1253702 A1 HK 1253702A1 HK 18112849 A HK18112849 A HK 18112849A HK 1253702 A1 HK1253702 A1 HK 1253702A1
Authority
HK
Hong Kong
Prior art keywords
bisphosphonates
polyphosphates
calcium carbonate
amorphous calcium
carbonate stabilized
Prior art date
Application number
HK18112849.8A
Other languages
English (en)
Inventor
約瑟夫‧本
伊加爾‧多夫‧布盧姆
哈凱‧摩西
本‧阿什肯納茲
Original Assignee
艾瑪菲克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾瑪菲克有限公司 filed Critical 艾瑪菲克有限公司
Publication of HK1253702A1 publication Critical patent/HK1253702A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18112849.8A 2015-06-04 2018-10-09 用聚磷酸/聚磷酸酯/聚磷酸鹽或雙膦酸/雙膦酸酯/雙膦酸鹽穩定的無定形碳酸鈣 HK1253702A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562170712P 2015-06-04 2015-06-04

Publications (1)

Publication Number Publication Date
HK1253702A1 true HK1253702A1 (zh) 2019-06-28

Family

ID=57440881

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18112848.9A HK1253701A1 (zh) 2015-06-04 2018-10-09 用於吸入施用、舌下施用或含服施用的無定形碳酸鈣的組合物
HK18112849.8A HK1253702A1 (zh) 2015-06-04 2018-10-09 用聚磷酸/聚磷酸酯/聚磷酸鹽或雙膦酸/雙膦酸酯/雙膦酸鹽穩定的無定形碳酸鈣

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18112848.9A HK1253701A1 (zh) 2015-06-04 2018-10-09 用於吸入施用、舌下施用或含服施用的無定形碳酸鈣的組合物

Country Status (13)

Country Link
US (4) US11052107B2 (zh)
EP (2) EP3302506A4 (zh)
JP (3) JP7039006B2 (zh)
KR (2) KR20180053632A (zh)
CN (3) CN117137872A (zh)
AU (3) AU2016273058B2 (zh)
BR (1) BR112017026131B1 (zh)
CA (2) CA2988060C (zh)
CL (2) CL2017003066A1 (zh)
HK (2) HK1253701A1 (zh)
IL (2) IL256064B2 (zh)
RU (2) RU2739563C2 (zh)
WO (2) WO2016193982A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2740453C2 (ru) * 2014-07-31 2021-01-14 Аморфикал Лтд. Неводные жидкие и полутвердые составы аморфного карбоната кальция
IL260548B2 (en) 2016-01-18 2024-04-01 Amorphical Ltd Stabilized amorphous calcium carbonate for the treatment of neurological, muscular and infertility diseases or conditions
BR112018014519A2 (pt) 2016-01-18 2018-12-11 Amorphical Ltd. carbonato de cálcio amorfo estabilizado como um suplemento para meios de cultura celular
JP7152785B2 (ja) 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
WO2018142403A1 (en) 2017-02-02 2018-08-09 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
CN110183876A (zh) * 2019-06-21 2019-08-30 中国矿业大学(北京) 重质碳酸钙改性剂、重质碳酸钙的改性方法、改性重质碳酸钙及其应用
MX2022000947A (es) * 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.
JP2023517927A (ja) * 2020-03-11 2023-04-27 アモーフィカル リミテッド． アシドーシスの治療のための非晶質炭酸カルシウム
KR102428137B1 (ko) * 2020-05-27 2022-08-03 세종대학교산학협력단 칼슘 보충용 조성물
EP4284343A4 (en) * 2021-01-28 2024-12-11 Amorphical Ltd. Particles comprising amorphous divalent metal carbonate
WO2024059842A2 (en) * 2022-09-16 2024-03-21 Augusta University Research Institute, Inc. Compositions and methods of minimizing long covid

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
JPS56124368A (en) * 1980-02-25 1981-09-30 Monsanto Co Stabilized amorphous calcium carbonate
EP0052677B1 (en) 1980-11-21 1985-01-09 Monsanto Company Concentrates for the preparation of carbonated beverages
US4964894A (en) 1986-03-31 1990-10-23 Freepons Donald E Plant growth regulators derived from chitin
EP0304987B1 (en) 1987-08-28 1992-11-11 Norwich Eaton Pharmaceuticals, Inc. Novel calcium supplements
CA1336328C (en) 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
EP0345375B1 (en) 1988-06-09 1995-03-22 N.V. Innogenetics S.A. HIV-3 retrovirus and its use
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US5460803A (en) 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5037639A (en) 1989-05-24 1991-08-06 American Dental Association Health Foundation Methods and compositions for mineralizing calcified tissues
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
JPH099871A (ja) 1995-07-03 1997-01-14 Kita Nippon Shokuhin Kk 菓 子
AU1366697A (en) 1995-12-26 1997-07-28 Holomed Aps A method and system for generating an x-ray image
JPH10236957A (ja) 1997-02-24 1998-09-08 Bankaku Souhonpo:Kk 骨粗鬆症の改善剤
US20060165784A1 (en) 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20030077604A1 (en) 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
EP1416916B1 (en) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
JP2003292453A (ja) 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JP2004081739A (ja) 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
EP1666046A4 (en) 2003-09-17 2007-10-03 Univ Pla 3Rd Military Medical USE OF N-ACETYL-D-AMINOGLYCOSAMINE FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CANCER AND METASTASES
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
KR100561231B1 (ko) 2004-05-18 2006-03-15 한국지질자원연구원 표면개질에 의한 비정질 탄산칼슘 제조방법
DK1758599T3 (en) 2004-05-26 2014-02-24 Univ Ben Gurion An orally administrable composition comprising stable amorphous calcium carbonate
WO2006043966A2 (en) 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
EP2374469A3 (en) 2004-12-21 2012-01-25 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
KR20170001758A (ko) 2004-12-22 2017-01-04 솔베이(소시에떼아노님) 알칼리 토금속 카르보네이트의 내산성 입자
DE102005047807A1 (de) 2005-06-04 2006-12-07 Solvay Infra Bad Hönningen GmbH Modifizierte Nanopartikel
US20070041506A1 (en) 2005-08-22 2007-02-22 Michelle Bottino Digital sensor holder
GB0522045D0 (en) 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
CA2637616A1 (en) 2006-01-19 2007-07-26 Osteotech, Inc. Injectable and moldable bone substitute materials
IL178495A (en) 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
EP2251018B1 (en) * 2007-10-22 2014-12-17 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins
WO2009087553A1 (en) 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits for administering bisphosphonates
CN101314031A (zh) 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US8999169B2 (en) 2008-10-17 2015-04-07 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
EP2396037A4 (en) 2009-02-12 2012-12-19 Aduro Material Ab COMPOSITION WITH A BIODEGRADABLE CARRIER FOR THE CONTROLLED DISPOSAL OF MEDICAMENTS
CN101580260B (zh) 2009-05-31 2011-04-27 河南大学 一种微乳液法制备无定形碳酸钙的方法
EP2598579B1 (de) 2010-07-30 2024-09-11 Schaefer Kalk GmbH & Co. KG Kugelförmige, amorphe calciumcarbonat-teilchen
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
CN102085356B (zh) 2010-12-28 2013-02-27 北京同仁堂健康药业股份有限公司 一种用于增加骨密度的组合物及其制备方法
CN103635428B (zh) 2011-04-28 2017-02-15 卡勒拉公司 使用碳酸钙和稳定剂的方法和组合物
ES2831699T3 (es) 2011-12-13 2021-06-09 Amorphical Ltd Un carbonato de calcio morfo para el tratamiento de la mala absorción de calcio y los trastornos metabólicos óseos
AU2013301121B2 (en) 2012-08-07 2016-11-24 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
EA201591152A1 (ru) * 2013-02-11 2016-03-31 Аморфикал Лтд. Аморфный карбонат кальция для ускоренного роста костной ткани
CN103663532B (zh) 2013-12-21 2015-10-28 中国科学院上海硅酸盐研究所 一种制备无定形碳酸钙纳米球的方法
RU2550865C1 (ru) 2013-12-30 2015-05-20 Меграбян Казарос Аршалуйсович Способ получения карбоната кальция
RU2740453C2 (ru) 2014-07-31 2021-01-14 Аморфикал Лтд. Неводные жидкие и полутвердые составы аморфного карбоната кальция
IL260548B2 (en) * 2016-01-18 2024-04-01 Amorphical Ltd Stabilized amorphous calcium carbonate for the treatment of neurological, muscular and infertility diseases or conditions

Also Published As

Publication number Publication date
RU2017145305A (ru) 2019-07-10
EP3302506A1 (en) 2018-04-11
RU2017145305A3 (zh) 2019-08-14
IL256064A (en) 2018-01-31
RU2017145291A3 (zh) 2019-11-14
JP7360738B2 (ja) 2023-10-13
WO2016193982A1 (en) 2016-12-08
AU2016273058A1 (en) 2018-01-18
US20210308178A1 (en) 2021-10-07
BR112017026131B1 (pt) 2023-11-21
RU2748976C2 (ru) 2021-06-02
AU2016273059B2 (en) 2021-07-15
JP2018516929A (ja) 2018-06-28
US12115184B2 (en) 2024-10-15
CN107921061A (zh) 2018-04-17
CA2988068A1 (en) 2016-12-08
JP2022046688A (ja) 2022-03-23
US20180153930A1 (en) 2018-06-07
EP3302506A4 (en) 2018-12-19
IL256065A (en) 2018-01-31
US11033576B2 (en) 2021-06-15
WO2016193983A1 (en) 2016-12-08
IL256064B1 (en) 2023-12-01
US11052107B2 (en) 2021-07-06
IL256064B2 (en) 2024-04-01
IL256065B2 (en) 2024-04-01
CL2017003066A1 (es) 2018-04-13
KR20180053632A (ko) 2018-05-23
RU2739563C2 (ru) 2020-12-25
EP3302505B1 (en) 2024-02-28
US20200345763A1 (en) 2020-11-05
AU2016273059A1 (en) 2018-01-18
CN107921060A (zh) 2018-04-17
EP3302505A1 (en) 2018-04-11
RU2017145291A (ru) 2019-07-09
CA2988068C (en) 2024-01-09
CN117137872A (zh) 2023-12-01
EP3302505C0 (en) 2024-02-28
US10758565B2 (en) 2020-09-01
CL2017003095A1 (es) 2018-05-11
CA2988060A1 (en) 2016-12-08
HK1253701A1 (zh) 2019-06-28
JP7039006B2 (ja) 2022-03-22
AU2021204073B2 (en) 2023-03-30
US20180140631A1 (en) 2018-05-24
BR112017026131A2 (pt) 2018-08-28
AU2021204073A1 (en) 2021-07-29
AU2016273058B2 (en) 2021-05-20
BR112017026125A2 (pt) 2018-08-28
KR20180057603A (ko) 2018-05-30
IL256065B1 (en) 2023-12-01
CA2988060C (en) 2023-09-05
EP3302505A4 (en) 2019-02-06
JP2018516930A (ja) 2018-06-28
JP7007716B2 (ja) 2022-01-25

Similar Documents

Publication Publication Date Title
HK1253702A1 (zh) 用聚磷酸/聚磷酸酯/聚磷酸鹽或雙膦酸/雙膦酸酯/雙膦酸鹽穩定的無定形碳酸鈣
IL267037A (en) A fume hood
IL269812A (en) Profortin inhibitor salts
IL250205A0 (en) Preparations containing dissolved amorphous calcium carbonate
IL267226A (en) Evaporator
ZA201801354B (en) Evaporation source
PT3172217T (pt) Retardadores de chama que contém fósforo
GB201604047D0 (en) Thread
IL252759A0 (en) Calcium carbonate for plant protection
HK1247125A1 (zh) 結晶化合物
GB2567279B (en) Salts
HUE052222T2 (hu) Sacubitril kalciumsók
HUP1600030A2 (en) Baricitinib salts
HK1253050A1 (zh) 穩定的富馬酸二烷基酯組合物
ZA201804357B (en) Calcium carbonate for particle boards
HK1255148A1 (zh) 結晶形式
HUE052716T2 (hu) Úszóval rendelkezõ párologtató olvasztótégely
GB2560534B (en) Calcium salts
IL266149A (en) Amorphous calcium carbonate for the treatment of leukemia
IL261795A (en) Crystalline form
PT3574553T (pt) Estabilização de transponder
IL240120A0 (en) Amorphous calcium carbonate for accelerated bone growth
AU365117S (en) Tongue Anteriorizor
HUP1300549A2 (hu) Kalciumkarbonátot tartalmazó levéltrágya.
ZA201408210B (en) Ammonium polyphosphate